The COA1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Raji B lymphocyte cell line, designed to disrupt the COA1 gene. This gene-edited product provides a loss-of-function model for studying mitochondrial complex IV assembly and function. The polyclonal nature ensures representation of diverse editing events within the population, avoiding clonal artifacts and enabling robust phenotypic analyses. These cells serve as a versatile tool for investigating the consequences of impaired oxidative phosphorylation in a B-cell context.
The parental Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma model derived from a human B lymphocyte. Raji cells exhibit characteristics of mature B cells, including surface immunoglobulin expression and secretion, making them an established system for studying B-cell biology, lymphomagenesis, and immunoglobulin production. Their robust growth and well-characterized signaling pathways provide a reliable background for genetic manipulation and functional assays.
COA1 encodes a mitochondrial inner membrane protein essential for the assembly and stabilization of cytochrome c oxidase (complex IV), the terminal enzyme of the mitochondrial electron transport chain. COA1 acts downstream of mitochondrial biogenesis regulators such as PPARGC1A (PGC-1??) and NRF1, and it interacts with key assembly factors including COX10, COX15, SURF1, SCO1, and SCO2 to facilitate incorporation of catalytic subunits COX1 and COX2 into the complex IV holoenzyme. Disruption of COA1 leads to defective complex IV assembly, impaired oxidative phosphorylation, reduced ATP synthesis, elevated reactive oxygen species (ROS), and activation of apoptotic pathways, reflecting the critical role of mitochondrial function in cellular energy metabolism and survival.
In the context of Raji B lymphocytes, COA1 knockout provides a unique model to explore how mitochondrial complex IV deficiency impacts B-cell physiology and lymphoma biology. Since lymphomas often undergo metabolic reprogramming, including alterations in oxidative phosphorylation and glycolysis, this polyclonal knockout population allows investigation of metabolic vulnerabilities in B-cell malignancies. Moreover, the interplay between mitochondrial dysfunction and immunoglobulin production can be examined, offering insights into diseases such as mitochondrial encephalomyopathy or immune dysregulation associated with mitochondrial defects.
Researchers can use these cells to study mitochondrial complex IV assembly, metabolic reprogramming in lymphoma, and mitochondrial toxicity. Typical assays include cytochrome c oxidase activity measurement, Seahorse extracellular flux analysis, ROS detection, and apoptosis assays. For further information, contact Ascent Research.
